Skip to main content
. 2021 Oct 5;47(11):1295–1302. doi: 10.1007/s00134-021-06475-2

Table 2.

Adjusted primary and secondary trial outcomes

Control, n (%) Intervention, n (%) Estimatea, (95% CI) P value
ICU mortality group, N 1555 1691
 ICU mortalityb 330 (21.2) 399 (23.5) 1.13 (0.82 to 1.54) 0.46
IVAC group, N 947 987
 IVACsb 24 (2.5) 48 (4.8) 1.06 (0.44 to 2.57) 0.90
BOAS group, N 154 182
 BOAS mean score (SD)c 11.24 (3.2) 10.47 (3.2) − 0.96 (1.75 to − 0.17) 0.02
BOAS categorized
 No dysfunction (5) 8 (5.0) 6 (3.1)
 Mild dysfunction (6–10) 50 (32.5) 86 (47.2)
 Moderate dysfunction (11–15) 80 (51.9) 78 (42.8)
 Severe dysfunction (16–20) 16 (10.4) 12 (6.5)
CPOT group, N 154 184
 CPOT mean score (SD) 2.32 (1.9) 2.27 (1.9) 1.62 (0.91 to 2.91) 0.10
CPOT categorizedc
 < 3 77 (50) 106 (57.6)
 ≥ 3 77 (50) 78 (42.3)
Time to extubation group (survivors), N 1061 994
 Time to extubation, median, days (IQR)b (SD) 2 (1–5) 2 (1–5) 1.03 (0.85 to 1.23) 0.79

BOAS Beck Oral Health Assessment Score, CPOT Critical-Care Pain Observational Tool, ICU Intensive Care Unit, IQR interquartile range, IVAC infection-related ventilator-associated, SD standard deviation

aOdds ratios for ICU mortality and CPOT dichotomized. Hazard ratio for IVAC and beta coefficient (change in average BOAS score in the intervention group vs control)

bP value based on an analysis that adjusts for age, sex, predicted mortality based on APACHE, operative status as well as secular trends and clustering of patients within ICU

cP values based on analysis adjusting for age, sex, admission category and number of tubes as well as the repeated measures per patient